CAMBRIDGE, Mass., Feb. 15, 2022 /PRNewswire/ -- Invaio Sciences,
Inc., a Flagship Pioneering company focused on unlocking the
potential of the planet's interdependent natural systems to solve
pressing agricultural, sustainability, and environmental
challenges, today announced the appointment of Hugh Grant to its Board of Directors.
Grant brings nearly 40 years of agricultural and corporate
leadership, including as Chairman, President, and Chief Executive
Officer of the former Monsanto Company, a global provider of
technology-based solutions and agricultural products. During his 15
years at the helm, Monsanto tripled sales to $14 billion and its share price rose 12 times. In
2018, Grant led the $60 billion sale
of Monsanto to Bayer AG.
"We are very pleased to welcome Hugh to our Board at a time
where we are actively developing and deploying Invaio's integrated
solutions to help growers and food and agricultural stakeholders
produce more nutritious food in a sustainable manner," said
Robert Berendes, Chairman of the
Board, Invaio Sciences, Inc. "Hugh's deep insights and experience
will be of tremendous value to scale our company for delivering
global impact."
"I'm impressed with the quality of the people and the strength
of the science. It's a winning combination in my experience," said
Grant.
Grant continued, "Invaio has developed a suite of groundbreaking
biological solutions and targeted delivery systems to address
critical crop health issues that have plagued the agricultural
industry for years. The company's potential for impact, not only
for farmers, but across the entire agricultural industry is
enormous, and I look forward to working with the leadership team
and Board of Directors to drive Invaio to commercial success."
About Hugh Grant
Hugh Grant was chairman and chief
executive officer of the former Monsanto Company. He joined
Monsanto in 1981 and spent the next 37 years working on three
continents in a variety of positions, including Executive Vice
President, Chief Operating Officer, and President. He held the
roles of Chairman and CEO from 2003 until his departure in 2018
upon the sale to Bayer.
Monsanto and Grant were recognized by numerous groups for
innovation, corporate responsibility, and business leadership
during his tenure. Grant has been named on Barron's list of Most
Respected CEOs, the Harvard Business Review's Top 50 Best
Performing CEOs, and recognized as "CEO of the Year" by Chief
Executive Magazine. In 2015, employee reviews also earned Grant an
honor on the Top 10 Highest-Rated CEOs list by Glassdoor.com.
Grant serves as lead director of PPG Industries, Inc., and
recently joined the board of Freeport McMoRan. He is also a former
member of Civic Progress in St. Louis,
Missouri. In 2011, he was inducted as a member of the
American Academy of Arts & Sciences.
Born in Larkhall, Scotland,
Grant earned a Bachelor of Science degree in agricultural zoology
with Honors at Glasgow University. He
also earned a post-graduate degree in agriculture at Edinburgh University and a Master of Business
Administration degree at the International Management Centre in
Buckingham, United Kingdom.
About Invaio
Invaio Sciences is a multi-platform
technology company that unlocks the potential of the planet's
interdependent systems to address pressing agricultural,
nutritional, and environmental challenges. Founded by Flagship
Pioneering in 2018, Invaio leverages discoveries from diverse
fields including human therapeutics, agriculture, environmental
science, and advanced manufacturing. The company's deep
understanding of the physiology of insects, plants, and trees,
together with its novel integrated solutions approach, promises to
refine agricultural practices and reduce the need for pesticides
globally. Invaio Sciences is dedicated to developing solutions that
are mindful of beneficial insects, bad for pests, and safer for us
all. For more information, please visit www.invaio.com or
follow us on Twitter or LinkedIn.
About Flagship Pioneering:
Flagship Pioneering conceives, creates, resources, and develops
first-in-category bioplatform companies to transform human health
and sustainability. Since its launch in 2000, the firm has, through
its Flagship Labs unit, applied its unique hypothesis-driven
innovation process to originate and foster more than 100 scientific
ventures, resulting in over $140
billion in aggregate value. To date, Flagship has deployed
over $2.6 billion in capital toward
the founding and growth of its pioneering companies alongside more
than $19 billion of follow-on
investments from other institutions. The current Flagship ecosystem
comprises 42 transformative companies, including Axcella Health
(NASDAQ: AXLA), Codiak BioSciences (NASDAQ: CDAK) Denali
Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO),
Foghorn Therapeutics (NASDAQ: FHTX), Indigo
Ag, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ:
MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology
(NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon
Therapeutics (NASDAQ: SGTX).
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invaio-sciences-strengthens-its-board-of-directors-with-the-appointment-of-hugh-grant-301480685.html
SOURCE Invaio Sciences